Evidence map›Paper›PMID 33931901›Full record

ArticleJournal of cutaneous pathology2021

Development of sacral/buttock retiform purpura as an ominous presenting sign of COVID-19 and clinical and histopathologic evolution during severe disease course.

Jeffrey D McBride, Jatin Narang, Robert Simonds, Shruti Agrawal, E Rene Rodriguez, Carmela D Tan, William M Baldwin, Nina Dvorina, Alison R Krywanczyk, Anthony P Fernandez

Open access · bronzeAbstract readCase Reports
In one paragraph

Article in Journal of cutaneous pathology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Jeffrey D McBrideDepartment of Dermatology, Cleveland Clinic, Cleveland, Ohio, USA.ORCID https://orcid.org/0000-0002-2167-9054
Jatin NarangCleveland Clinic Lerner College of Medicine, Cleveland, Ohio, USA.
Robert SimondsDepartment of Dermatology, Cleveland Clinic, Cleveland, Ohio, USA.
Shruti AgrawalDepartment of Dermatology, Cleveland Clinic, Cleveland, Ohio, USA.
E Rene RodriguezDepartment of Pathology, Cleveland Clinic, Cleveland, Ohio, USA.
Carmela D TanDepartment of Pathology, Cleveland Clinic, Cleveland, Ohio, USA.
William M BaldwinDepartment of Inflammation and Immunity, Cleveland Clinic Lerner Research Institute, Cleveland, Ohio, USA.
Nina DvorinaDepartment of Inflammation and Immunity, Cleveland Clinic Lerner Research Institute, Cleveland, Ohio, USA.
Alison R KrywanczykDepartment of Pathology, Cleveland Clinic, Cleveland, Ohio, USA.
Anthony P FernandezDepartment of Dermatology, Cleveland Clinic, Cleveland, Ohio, USA.ORCID https://orcid.org/0000-0003-4490-8427
Cleveland Clinic · USCleveland Clinic Lerner College of Medicine · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Retiform purpura has been described as a relatively frequent cutaneous finding in patients with coronavirus disease 2019 (COVID-19). The etiology is hypothesized to be related to thrombotic vasculopathy based on lesional biopsy specimen findings, but the pathogenesis of the vasculopathy is not completely understood. Here, we present a case of a retiform purpuric patch on the sacrum/buttocks in a hospitalized patient prior to subsequent diagnosis of COVID-19 and an eventual fatal disease course. Two lesional biopsy specimens at different time points in the disease course revealed thrombotic vasculopathy, despite therapeutic anticoagulation. Detailed histopathologic evaluation using immunohistochemical markers suggest the etiology of the vasculopathy involves both persistent complement activation and platelet aggregation, which possibly promote ongoing thrombus formation. This case highlights that sacral/buttock retiform purpuric patches may be a presenting sign of infection with SARS-CoV-2 virus and may represent an ominous sign supporting a future severe disease course. In addition, biopsy specimen findings at separate time points demonstrate that cutaneous vasculopathy may persist despite adequate systemic anticoagulation, possibly due to the combination of persistent complement and platelet activation. Finally, occlusive thrombi in sacral/buttock retiform purpuric patches may contribute to future ulceration and significant cutaneous morbidity in patients who survive COVID-19.

Indexed as

AgedAnticoagulantsBiopsyButtocksCalciphylaxisComplement ActivationCOVID-19Diagnosis, DifferentialDisease ProgressionFatal OutcomeFemaleHumansInpatientsPlatelet AggregationPurpuraSacrumAnticoagulantscomplementCOVID-19plateletsretiform purpurathrombotic vasculopathy

Identifiers

PMID33931901
PMCPMC8239708
OpenAlexW3159309714

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.